Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix's positive outlook is bolstered by compelling data from the Phase 3 SOL-1 trial of AXPAXLI in wet AMD, which demonstrated significant visual acuity gains and durability across various patient subgroups. The results indicated that AXPAXLI outperformed aflibercept with a notable median time difference in Central Subfield Thickness improvements, potentially expediting its FDA approval timeline. Additionally, the consistent efficacy exhibited in visual acuity gains suggests a strong foundation for ongoing development, particularly in the treatment of diabetic retinopathy, enhancing confidence in the company's clinical pipeline.

Bears say

Ocular Therapeutix has faced considerable stock pressure, exemplified by a ~22% decline following the successful meeting of a primary endpoint in clinical trials, raising concerns among investors. The company has consistently reported significant losses since its inception, indicating ongoing financial challenges that could hinder future growth and stability. Additionally, competitive risks from both existing and emerging therapies may adversely affect Ocular's market penetration and pricing strategies, further contributing to a negative outlook on the stock.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.